Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Blood (2015) 126 (6): 779–789.

https://doi.org/10.1182/blood-2015-02-628669

Published: 2015

Includes: Supplemental data

Journal Articles

Absence Of Mutation In Cereblon (CRBN) and DNA Damage Binding Protein 1 (DDB1) Genes In Myeloma Cells and Patients and Its Clinical Significance

Anjan Thakurta, PhD, Anita K Gandhi, PhD, Michelle Waldman, MS, Chad C. Bjorklund, Ph.D., Suzanne Lentzsch, MD, PhD, Stephen A Schey, MD, Yolanda Calle, PhD, Rajani Chelliah, BSc, MSc, Robert Z. Orlowski, M.D., Ph.D, Anup Madan, PhD, Yuhong Ning, Derek Mendy, B.S., Antonia Lopez-Girona, PhD, Peter H Schafer, PhD, Herve Avet-Loiseau, MD, Rajesh Chopra, MD

Blood (2013) 122 (21): 3139.

https://doi.org/10.1182/blood.V122.21.3139.3139

Published: 2013

Journal Articles

Inhibition of B Cell Differentiation to the Plasmablast and Plasma Cell Lineage by CC-220, a Potent Modulator of the CRBN E3 Ubiquitin Ligase Complex

Peter H Schafer, PhD, Lori Capone, BS, Lei Wu, MS, ECFMG, Rajesh Chopra, MD, PhD

Blood (2012) 120 (21): 3279.

https://doi.org/10.1182/blood.V120.21.3279.3279

Published: 2012

Journal Articles

Lenalidomide Efficacy in Activated B-Cell-Like Subtype Diffuse Large B-Cell Lymphoma Is Dependent Upon IRF4 and Cereblon Expression

Ling-Hua Zhang, PhD, Jolanta Kosek, BA, Maria Wang, Ph.D., Carla Heise, PhD, Peter H Schafer, PhD, Rajesh Chopra, MD, PhD

Blood (2012) 120 (21): 3287.

https://doi.org/10.1182/blood.V120.21.3287.3287

Published: 2012

Journal Articles

Targeting Cereblon with the High Affinity Immunomodulatory Compound CC-220: A Novel Therapeutic Agent for B Cell Dyscrasias

Peter H Schafer, PhD, Emily Rychak, PhD, Derek Mendy, BS, Anastasia Parton, BA, Lori Capone, BS, Antonia Lopez-Girona, PhD, Jilly F Evans, PhD, Tom O Daniel, MD, PhD, Rajesh Chopra, MD, PhD

Blood (2012) 120 (21): 1055.

https://doi.org/10.1182/blood.V120.21.1055.1055

Published: 2012

Journal Articles

Detection and Quantification of Cereblon Protein and mRNA in Multiple Myeloma Cell Lines and Primary CD138 + multiple Myeloma Cells

Anita K Gandhi, PhD, Herve Avet-Loiseau, MD, Michelle Waldman, MS, Anjan Thakurta, PhD, Sharon L Aukerman, PhD, Gengxin Chen, PhD, Derek Mendy, BS, Emily Rychak, PhD, Karen Miller, Svetlana Gaidarova, MS, Michael Gonzales, Brian Cathers, PhD, Peter H Schafer, PhD, Tom O Daniel, MD, PhD, Antonia Lopez-Girona, PhD, Rajesh Chopra, MD, PhD

Blood (2012) 120 (21): 4043.

https://doi.org/10.1182/blood.V120.21.4043.4043

Published: 2012

Journal Articles

CC-122 Is a Novel Pleiotropic Pathway Modifier with Potent in Vitro Immunomodulatory and Anti-Angiogenic Properties and in Vivo Anti-Tumor Activity in Hematological Cancers.

Anita K Gandhi, PhD, Derek Mendy, BS, Anastasia Parton, BA, Lei Wu, MS, ECFMG, Jolanta Kosek, BA, Ling-Hua Zhang, PhD, Lori Capone, BS, Antonia Lopez-Girona, PhD, Peter H Schafer, PhD, Rajesh Chopra, MD, PhD

Blood (2012) 120 (21): 2963.

https://doi.org/10.1182/blood.V120.21.2963.2963

Published: 2012

Journal Articles

Direct Binding with Cereblon Mediates the Antiproliferative and Immunomodulatory Action of Lenalidomide and Pomalidomide

Antonia Lopez-Girona, Ph.D., Derek Mendy, Karen Miller, Anita K Gandhi, Jian Kang, Gilles Carmel, Mahan Abbasian, Afshin Mahmoudi, Pilgrim Jackson, Brian Cathers, Emily Rychak, Normand Richard, Helen A Brady, Peter H Schafer, Jilly F Evans, Tom O Daniel, Rajesh Chopra

Blood (2011) 118 (21): 738.

https://doi.org/10.1182/blood.V118.21.738.738

Published: 2011

Journal Articles

Treatment of MCL Cells with Combined Rituximab and Lenalidomide Enhances NK-Mediated Synapse Formation and Cell Killing.

Svetlana Gaidarova, Laura G Corral, Emilia Glezer, Peter H Schafer, Antonia Lopez-Girona

Blood (2009) 114 (22): 1687.

https://doi.org/10.1182/blood.V114.22.1687.1687

Published: 2009

Journal Articles

Lenalidomide Shuts Down the Translational Machinery in Multiple Myeloma Cells Resulting in Down-Regulation of Critical Transcription Factors Such as C/EBPβ and IRF4.

Shirong Li, PhD, Rekha Pal, PhD, Deborah L Galson, Ph.D., Peter H Schafer, PhD, Hongjiao Ouyang, DDS, PhD, Markus Y Mapara, MD, PhD, Suzanne Lentzsch, MD, PhD

Blood (2009) 114 (22): 1844.

https://doi.org/10.1182/blood.V114.22.1844.1844

Published: 2009

Journal Articles

Lenalidomide Alone and in Combination with Rituximab Enhances NK Cell Immune Synapse Formation in Chronic Lymphocytic Leukemia (CLL) Cells in Vitro through Activation of Rho and Rac1 GTPases.

Svetlana Gaidarova, JianWu Li, M.D., Laura G Corral, Emilia Glezer, Peter H Schafer, Weilin Xie, Antonia Lopez-Girona, Bruce D. Cheson, MD, Brydon Bennett

Blood (2009) 114 (22): 3441.

https://doi.org/10.1182/blood.V114.22.3441.3441

Published: 2009

Journal Articles

Lenalidomide Inhibits Multiple Myeloma Cell Proliferation in Vitro Via Its Effect On Expression of Oncogenes and Tumor Suppressor Genes.

Ling-Hua Zhang, Mary Adams, Jolanta Kosek, Peter H Schafer, J. Blake Bartlett

Blood (2009) 114 (22): 2855.

https://doi.org/10.1182/blood.V114.22.2855.2855

Published: 2009

Journal Articles

Anti-Proliferative and Apoptotic Activity of Lenalidomide in Combination with Rituximab in Follicular Lymphoma: An in Vitro and Ex Vivo Analysis in Follicular Lymphoma Cells.

Anita K Gandhi, Jian Kang, Lori Capone, Marianna Shafarenko, PhD, Peter H Schafer

Blood (2009) 114 (22): 3723.

https://doi.org/10.1182/blood.V114.22.3723.3723

Published: 2009

Journal Articles

Lenalidomide Augments Immune Responses to Prevnar Vaccination in Relapsed Myeloma Patients: Implications for Cancer and Infectious Vaccines.

Kimberly Ann Noonan, MPH, BS, Anna Ferguson, RN, Amy Emerling, Lakshmi Rudraraju, M.S., Carol A. Huff, MD, Peter H Schafer, Ivan M. Borrello, MD

Blood (2009) 114 (22): 1864.

https://doi.org/10.1182/blood.V114.22.1864.1864

Published: 2009

Journal Articles

Opposing Effects of Dexamethasone on Lenalidomide Activity in Multiple Myeloma: Additive/Synergistic Effects on Anti-Proliferative Activity on Myeloma Cells and Antagonistic Effects on Immune Function

Peter H Schafer, Anita K Gandhi, Ling-Hua Zhang, Jian Kang, Lori Capone, Stacey Parton, Lei Wu, Blake Bartlett

Blood (2008) 112 (11): 2761.

https://doi.org/10.1182/blood.V112.11.2761.2761

Published: 2008

Journal Articles

Stimulation of T Cells by Lenalidomide Involves Putative Lenalidomide Binding Proteins CD3-Epsilon-Associated Protein and GDP-Mannose Pyrophosphorylase a

Ani ta K Gandhi, Audrey Rogovitz, Antonia Lopez-Girona, Derek Mendy, Lisa Morrison, Weilin Xie, Peter H Schafer

Blood (2008) 112 (11): 2606.

https://doi.org/10.1182/blood.V112.11.2606.2606

Published: 2008

Journal Articles

Direct Inhibitory Effects of Lenalidomide on the Proliferation and VEGF Production of Non-Hodgkin Lymphoma Cells Are Associated with Increased SPARC Expression

Ling-Hua Zhang, Peter H Schafer, George Muller, David Stirling, Blake Bartlett

Blood (2008) 112 (11): 2612.

https://doi.org/10.1182/blood.V112.11.2612.2612

Published: 2008

Journal Articles

Antiproliferative Effects of Lenalidomide in Combination with Chemotherapeutic Agents in Lymphoma Cell Lines

Anita K Gandhi, Jian Kang, Lori Capone, Ling-Hua Zhang, Blake Bartlett, Dennis Pietronegro, Annette Ervin-Haynes, Peter H Schafer

Blood (2008) 112 (11): 4990.

https://doi.org/10.1182/blood.V112.11.4990.4990

Published: 2008

Journal Articles

Lenalidomide Displays Anti-Proliferative Activity and Combination Effects with Chemotherapeutic Agents Against a Burkitt’s Lymphoma Cell Line.

Anita K. Gandhi, PhD, Jian Kang, BS, Ling-Hua Zhang, PhD, Blake Bartlett, PhD, Peter H. Schafer, PhD, David I. Stirling, PhD

Blood (2007) 110 (11): 4516.

https://doi.org/10.1182/blood.V110.11.4516.4516

Published: 2007

NARROW

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Absence Of Mutation In Cereblon (CRBN) and DNA Damage Binding Protein 1 (DDB1) Genes In Myeloma Cells and Patients and Its Clinical Significance

Inhibition of B Cell Differentiation to the Plasmablast and Plasma Cell Lineage by CC-220, a Potent Modulator of the CRBN E3 Ubiquitin Ligase Complex

Lenalidomide Efficacy in Activated B-Cell-Like Subtype Diffuse Large B-Cell Lymphoma Is Dependent Upon IRF4 and Cereblon Expression

Targeting Cereblon with the High Affinity Immunomodulatory Compound CC-220: A Novel Therapeutic Agent for B Cell Dyscrasias

Detection and Quantification of Cereblon Protein and mRNA in Multiple Myeloma Cell Lines and Primary CD138 + multiple Myeloma Cells

CC-122 Is a Novel Pleiotropic Pathway Modifier with Potent in Vitro Immunomodulatory and Anti-Angiogenic Properties and in Vivo Anti-Tumor Activity in Hematological Cancers.

Direct Binding with Cereblon Mediates the Antiproliferative and Immunomodulatory Action of Lenalidomide and Pomalidomide

Treatment of MCL Cells with Combined Rituximab and Lenalidomide Enhances NK-Mediated Synapse Formation and Cell Killing.

Lenalidomide Shuts Down the Translational Machinery in Multiple Myeloma Cells Resulting in Down-Regulation of Critical Transcription Factors Such as C/EBPβ and IRF4.

Lenalidomide Alone and in Combination with Rituximab Enhances NK Cell Immune Synapse Formation in Chronic Lymphocytic Leukemia (CLL) Cells in Vitro through Activation of Rho and Rac1 GTPases.

Lenalidomide Inhibits Multiple Myeloma Cell Proliferation in Vitro Via Its Effect On Expression of Oncogenes and Tumor Suppressor Genes.

Anti-Proliferative and Apoptotic Activity of Lenalidomide in Combination with Rituximab in Follicular Lymphoma: An in Vitro and Ex Vivo Analysis in Follicular Lymphoma Cells.

Lenalidomide Augments Immune Responses to Prevnar Vaccination in Relapsed Myeloma Patients: Implications for Cancer and Infectious Vaccines.

Opposing Effects of Dexamethasone on Lenalidomide Activity in Multiple Myeloma: Additive/Synergistic Effects on Anti-Proliferative Activity on Myeloma Cells and Antagonistic Effects on Immune Function

Stimulation of T Cells by Lenalidomide Involves Putative Lenalidomide Binding Proteins CD3-Epsilon-Associated Protein and GDP-Mannose Pyrophosphorylase a

Direct Inhibitory Effects of Lenalidomide on the Proliferation and VEGF Production of Non-Hodgkin Lymphoma Cells Are Associated with Increased SPARC Expression

Antiproliferative Effects of Lenalidomide in Combination with Chemotherapeutic Agents in Lymphoma Cell Lines

Lenalidomide Displays Anti-Proliferative Activity and Combination Effects with Chemotherapeutic Agents Against a Burkitt’s Lymphoma Cell Line.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only